Welcome to our dedicated page for Vtv Therapeutics SEC filings (Ticker: VTVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The vTv Therapeutics Inc. (VTVT) SEC filings page on Stock Titan provides access to the company’s official disclosures as a Nasdaq-listed issuer of Class A common stock. vTv Therapeutics is a late-stage biopharmaceutical company focused on oral, small molecule drug candidates for diabetes and other chronic diseases, with a clinical pipeline led by cadisegliatin (TTP399), a liver-selective glucokinase activator in Phase 3 development for type 1 diabetes.
Through this page, users can review current and historical filings submitted to the U.S. Securities and Exchange Commission, including Forms 8‑K that detail material events. Recent 8‑K filings describe quarterly financial results, private placement transactions involving common stock and warrants, and participation in investor conferences. For example, vTv Therapeutics has filed 8‑Ks outlining an approximately $80 million private placement of Class A common shares and pre-funded warrants, along with accompanying warrants, and has disclosed registration rights agreements for the resale of these securities.
Investors interested in vTv Therapeutics’ development of cadisegliatin and other small molecules can use this filings page to locate quarterly and annual reports (Forms 10‑Q and 10‑K when available), which typically summarize research and development spending, cash position, and risk factors associated with drug development. The page also surfaces current reports on material events (Form 8‑K), which may include updates on financing arrangements, clinical milestones, and other significant corporate actions.
Stock Titan complements the raw SEC documents with AI-powered summaries designed to highlight key points from lengthy filings, helping readers quickly understand topics such as capital structure changes, contract liabilities, warrant terms, and the financial context for ongoing clinical trials. Users can also track filings that relate to equity issuances and warrants, which are important for understanding potential dilution and funding of the cadisegliatin program.
By reviewing vTv Therapeutics’ SEC filings in one place, investors and researchers can follow how the company reports its financial condition, capital-raising activities, and material developments tied to its late-stage diabetes-focused pipeline.
vTv Therapeutics Inc. Schedule 13G reports that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander together disclose shared voting and dispositive power over 198,237 shares of Class A Common Stock, representing 5.0% of the class as shown on the cover page dated 03/24/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and includes a Joint Filing Agreement dated 03/26/2026.
vTv Therapeutics Inc. furnished an updated investor presentation highlighting its diabetes-focused pipeline. The deck centers on cadisegliatin (TTP399), a hepatoselective glucokinase activator in Phase 3 CATT1 for type 1 diabetes, which has FDA Breakthrough Therapy Designation and aims to be the first oral adjunctive T1D therapy in the U.S. Phase 2 SimpliciT1 data showed a 0.36% HbA1c reduction versus insulin alone and about 50% fewer symptomatic hypoglycemic episodes, with no diabetic ketoacidosis and a generally similar adverse-event profile to placebo. An earlier T2D study showed a 0.9% HbA1c reduction versus metformin. The presentation states cash of $88.9 as of 12/31/2025 plus an additional $20 received on 2/2/2026, which the company says supports operations past the expected CATT1 topline readout. vTv also outlines partnered programs in psoriasis, cancer, and regional T2D markets, and internal assets including an oral GLP-1 agonist (TTP273) and Nrf2/Bach1 modulators targeting oxidative inflammation.
vTv Therapeutics Inc. reported fourth quarter and full year 2025 results and provided a clinical and corporate update. Cash and cash equivalents were $88.9 million as of December 31, 2025, up from $36.7 million a year earlier, mainly from prior private financing.
For 2025, research and development expenses rose to $17.9 million and general and administrative expenses to $14.9 million. Net loss attributable to vTv shareholders was $27.0 million, or $3.20 per basic share.
The company received a $20.0 million upfront payment in February 2026 from an amended global license with Newsoara for PDE4 inhibitor HPP737, with potential future milestones and royalties. vTv expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin for type 1 diabetes in the third quarter of 2026 and states that its strengthened balance sheet funds operations well past the anticipated Phase 3 topline readout.
vTv Therapeutics Inc. files its annual report describing a late-stage biopharmaceutical business focused on orally administered therapies for metabolic and inflammatory diseases, led by cadisegliatin (TTP399) for type 1 diabetes.
Cadisegliatin has FDA Breakthrough Therapy designation and is in the Phase 3 CATT1 trial, which will randomize 150 patients to assess reductions in severe hypoglycemia and improvements in HbA1c. The program recently resumed after the FDA lifted a clinical hold in March 2025.
The company broadened its pipeline with candidates targeting GLP‑1, RAGE, PPAR‑δ and Nrf2/Bach1 pathways and expanded partnered programs, including global rights to PDE4 inhibitor HPP737 licensed to Newsoara. In 2025 it closed an $80 million private placement, plus a $20 million upfront payment from Newsoara, supporting development beyond topline CATT1 data. As of March 10, 2026, vTv had 3,938,654 Class A common shares outstanding.
vTv Therapeutics Inc. released an updated investor presentation outlining its diabetes-focused pipeline and financial position. The company highlights cadisegliatin, an oral glucokinase activator in Phase 3 development as a potential first oral adjunctive therapy for type 1 diabetes in the U.S., with topline CATT1 study data targeted for the second half of 2026.
The presentation cites prior Phase 2 data in T1D showing a 0.36% reduction in HbA1c versus insulin alone and a 50% reduction in symptomatic hypoglycemic episodes, with no diabetic ketoacidosis. Cadisegliatin has FDA Breakthrough Therapy Designation. vTv reports $98 million in cash as of September 30, 2025, plus an additional $20 million received on February 2, 2026, which it says provides runway well past the CATT1 topline readout.
The company also describes additional clinical and preclinical programs in immunology, inflammation, metabolism, oncology, obesity, and oxidative inflammation, along with regional partnerships that could generate royalties and shared economics. Management emphasizes its experienced leadership team and positions the broader portfolio as offering potential non-dilutive funding and future revenue streams.
vTv Therapeutics Inc. executive vice president and CFO Michael Stephen Tung received a grant of employee stock options reported as a Form 4 transaction. The award covers 44,969 options with an exercise price of $36.92 per share, increasing his directly held option position to 89,969 options following the grant. According to the footnote, the options vest 25% on the first anniversary of the grant date and then in equal quarterly installments afterward, spreading the ability to exercise over time.
vTv Therapeutics Inc. reported an insider equity award for its President, CEO and Executive Chairperson, Paul J. Sekhri. On February 17, 2026, he was granted stock options tied to 140,000 shares of Class A common stock at an exercise price of $36.92 per share. The options vest 25% on the first anniversary of the grant date and then in equal quarterly installments. Following this grant, Sekhri’s directly held Class A interest reported in this filing totals 392,212 shares.
vTv Therapeutics Inc. reported that its subsidiary vTv Therapeutics LLC entered into a Second Amendment to its license agreement with Newsoara Biopharma Co., Ltd. on January 30, 2026. The amendment expands Newsoara’s rights to vTv’s PDE4 inhibitor HPP737 to cover all countries.
In return, Newsoara will pay an upfront fee of $20 million, development milestone payments of up to $50 million, and sales-related milestones of up to $65 million. The agreement also includes royalties in the mid single digits based on sales volumes, creating multiple potential revenue streams tied to HPP737’s progress and commercial performance.
vTv Therapeutics Inc. reported Q3 2025 results. The company recorded no revenue, with operating expenses of $10.7 million (research and development $7.0 million; general and administrative $3.7 million), leading to a net loss attributable to vTv of $8.7 million and basic/diluted loss per share of $1.08.
Liquidity improved, with cash and cash equivalents $98.5 million at September 30, 2025, supported by an August private placement that brought aggregate gross proceeds of approximately $80.0 million (net financing cash inflow $77.8 million). Management now indicates there is no longer substantial doubt about the company’s ability to continue as a going concern for at least twelve months from issuance.
Development advanced: the FDA removed the cadisegliatin clinical hold on March 14, 2025, and the CATT1 Phase 3 protocol was shortened to six months; top‑line data are expected in the second half of 2026. Shares outstanding were 3,938,018 Class A and 241 Class B as of November 6, 2025.